DIASENSE Due Diligence

Run due diligence on DIASENSE: check compliance and get alerts when suppliers or ownership change.

Denmark · owned by Independent (Denmark) · diasense.dk · 9 vendors

DIASENSE develops Quantum Diamond Magnetic Microscopes for semiconductor chip failure analysis and production monitoring. Their cutting-edge quantum sensing technology enables contactless, high-resolution analysis of integrated circuits to detect failure mechanisms invisible to traditional techniques.

Resilience scores

Technology vendors

Insights

Last updated 2026-09-13 · revision 15

9 direct vendors, 153 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Compliance

3 in-scope frameworks identified; showing 3.

GDPR (source) — No public evidence

As a Danish company with employees, customers, and business operations, DIASENSE processes personal data (employee records, customer contacts, supplier information) within the EU.

SOC 2 (source) — No public evidence

Relevant if DIASENSE provides data analysis services or cloud-based monitoring that handles customer data.

ISO 27001 (source) — No public evidence

Highly relevant for technology companies handling sensitive IP and customer data in the semiconductor industry.

Financials

Three-year financials

Financial Resilience Score: 6/10

DIASENSE ApS demonstrates moderate resilience underpinned by strong institutional backing and proprietary intellectual property. Securing a €2.5 million seed round from Vækstfonden and Pre-Seed Ventures provides a significant financial runway and validates the commercial potential of its SU-8 based biosensor technology. The company's lean operational structure and focus on a high-growth market like point-of-care diagnostics further enhance its foundational stability during the pre-commercial phase. However, the company faces substantial risks typical of early-stage MedTech ventures, primarily its total dependency on external funding and lack of revenue. The path to commercialization is contingent upon navigating complex regulatory hurdles, such as CE marking under IVDR, and achieving successful clinical validation. Any delays in these processes or failure to secure a subsequent Series A funding round could critically impact the company's ability to sustain operations.

Key strengths: Strong Investor Backing (Vækstfonden, Pre-Seed Ventures), Proprietary Patented SU-8 Biosensor Technology, Large Addressable Point-of-Care Market, Lean Operational Structure

Risk factors: Total Revenue Dependency on Cash Reserves, Stringent Regulatory Approval Hurdles (CE Mark/FDA), Market Adoption and Competition Risk, Requirement for Future Series A Funding

Revenue by geography

Revenue by product/service

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report